It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Discover effective wealth management strategies tailored for young adults. Start building your wealth for a prosperous future.
20,949 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Rocket Lab’s stock jumped about 118% in the last year, but a big move doesn’t always mean a lasting uptrend. This art...
Investors fear there is no clean exit from the Iran conflict, leaving Wall Street bracing for volatility as options f...
Netflix signals a major strategic shift toward live television and third-party distributions to boost engagement as a...
Broadcom’s AI-driven revenue surge is reshaping the chip landscape, prompting persistent buying from a longtime inves...
A two-earner household saw its pay climb dramatically, yet debt and stress grew. This report examines why the money d...
Hynix’s move onto the Nasdaq marks a watershed moment for foreign listings in the U.S. tech space. This article break...
As markets rally into mid-2026, analysts spotlight five stock setups where Wall Street sees the most upside, driven b...
As the three-year mark of the Ripple-SEC ruling arrives, XRP has moved from regulator target to institutional asset, ...
Microsoft’s Satya Nadella signals a data-centric AI strategy, arguing buyers must reveal proprietary know-how to unlo...
With Senate leadership sidelined, key defense funding plans face delay as Iran tensions intensify and midterms loom. ...
Oil price moves can lift bank profits in certain scenarios. This article breaks down two upside reasons higher prices...